Merck KGaA submitted an application to the European Medicines Agency or EMA to extend the indication of Rebif, its treatment for multiple sclerosis or MS. The company added that the requested label extension is for the use of Rebif in patients who have experienced a single demyelinating event, an early sign of the disease, and who are at high risk of converting to MS..... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1901